How effective is the vaccine against covid-19 when you have a transplant, suffer from kidney failure or have been treated for cancer? To find the answer to this question, theANRS/Emerging Infectious Diseases research agency is launching a vast study involving 10,500 patients. This study should last two years.
In these patients with a weakened immune system, the immune response is necessarily worse than in healthy people. “The objective is to know how best to protect these patients”told AFP infectious disease specialist Odile Launay, responsible for this study called Cov-Popart(for Covid-19 vaccine cohort of special populations). To do this, the researchers will therefore compare the immune response of patients at 1, 6, 12 and 24 months after their last dose of vaccine, while also taking into account age, type of vaccine, type of treatment followed, etc
A recruitment of 10,500 patients
The researchers planned to include in their study:
- 800 patients under chemotherapy or immunotherapy due to a solid tumor
- 700 solid organ transplant recipients
- 350 allogeneic stem cell transplant patients
- 350 with chronic renal failure and dialysis
- 1,950 patients with autoimmune diseases on immunosuppressive therapy
- 300 patients with hypogammaglobulinemia
- 1400 patients suffering from obesity
- 1400 diabetics
- 1400 HIV patients
To these sub-groups will be added 1,850 people aged 18 to 75 or over, free from any chronic disease, for comparison.
The study launched via the Covireivac platform will be carried out in around thirty hospitals and should last until September 2024.
Read also :
- Can we really boost our immunity? 5 nutritionist tips
- How the immune system works in 9 true/false
- Coronavirus and blood groups: what we know
- Covid reinfection: more frequent after 65 years
